November 20, 2024

Paul A. Romness
Chief Executive Officer
OS Therapies Incorporated
115 Pullman Crossing Road, Suite #103
Grasonville, MD 21638

       Re: OS Therapies Incorporated
           Registration Statement on Form S-1
           Filed November 12, 2024
           File No. 333-283171
Dear Paul A. Romness:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Cover Page

1.     We note you are registering the resale of common stock to be issued
pursuant to the
       equity line financing with Square Gate Capital Master Fund LLC. Please
specify the
       number of shares being registered under the equity line financing and
ensure that
       Square Gate Capital Master Fund LLC is also named as an underwriter
throughout the
       filing, where appropriate, including the Selling Stockholder and Plan of
Distribution
       sections. Refer to Securities Act Sections Compliance and Disclosure
Interpretation
       Question 139.13 for guidance.
Plan of Distribution, page 101

2.     We note your disclosure on page 102 that Regulation M    may apply to
sales of shares
       in the market and to the activities of the Selling Securityholder and
its affiliates.
 November 20, 2024
Page 2

       Please revise to disclose how the provisions of Regulation M may
prohibit the Selling
       Securityholder and any other distribution participants that are
participating in the
       distribution of your securities from:
           engaging in market making activities (e.g., placing bids or making
purchases to
           stabilize the price of the ordinary shares) while the equity line is
in effect; and
           purchasing shares in the open market while the equity line is in
effect.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

      Please contact Doris Stacey Gama at 202-551-3188 or Chris Edwards at
202-551-
6761 with any other questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Spencer G. Feldman, Esq.